Implants

Sight Sciences OMNI® Surgical System to Be Featured in Multiple Presentations at the 2022 European Society of Cataract and Refractive Surgery Annual Meeting

Compendium of clinical presentations includes studies with up to 3.5 years of patient follow-up and over 400 eyes treated in...

Ocuphire Announces Upcoming Presentations at European Forum 2022, Eyecelerator@AAO 2022 and the American Academy of Ophthalmology 2022 Annual Meeting

FARMINGTON HILLS, Mich., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused...

Sight Sciences Announces Long-Term Safety and Effectiveness Data of Standalone Use of the OMNI® Surgical System in Patients with Open Angle Glaucoma

Three-year, standalone (not combined with cataract surgery) data shows the non-implantable minimally invasive glaucoma surgery effectively reduces intraocular pressure and...

ContraFect Announces Publication on Exebacase and CF-296 Demonstrating Potent In Vivo Antimicrobial Activity in Implant-Associated MRSA Osteomyelitis

YONKERS, N.Y., Aug. 15, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery...

error: Content is protected !!